Navigating time and uncertainty in health technology appraisal: Would a map help?

PharmacoEconomics

Volumn 31, Issue 9, 2013, Pages 731-737

  McCabe, Christopher ^a   Edlin, Richard ^b   Hall, Peter ^c  

^a UNIVERSITY OF ALBERTA   (Canada)

^b UNIVERSITY OF AUCKLAND   (New Zealand)

^c UNIVERSITY OF LEEDS   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; COST EFFECTIVENESS ANALYSIS; DECISION MAKING; HEALTH CARE SYSTEM; HUMAN; PRIORITY JOURNAL; PROBABILITY; REIMBURSEMENT; TIME;

COST-BENEFIT ANALYSIS; DECISION MAKING; DELIVERY OF HEALTH CARE; HEALTH CARE COSTS; HUMANS; TECHNOLOGY, HIGH-COST; TIME FACTORS; UNCERTAINTY;

EID: 84883532909     PISSN: 11707690     EISSN: 11792027     Source Type: Journal    
DOI: 10.1007/s40273-013-0077-y     Document Type: Article

References (24)

1. Van Hout B, Al J, Gordon G, Rutten F. Costs, effects and C/E ratios alongside a clinical trial. Health Econ. 1994;3(5):309-19.
2. Drummond M, Sculpher M, Torrance G, O'Brien B, Stoddart G. Methods for the economic evaluation of health care programmes. 3rd ed. Oxford: Oxford University Press; 2005.
3. Fenwick E, Claxton K, Sculpher M. Representing uncertainty: the role of cost-effectiveness acceptability curves. Health Econ. 2001;10:779-87. (Pubitemid 34041389)
4. Eckermann S, Willan A. Presenting evidence and summary measures to best inform societal decisions when comparing multiple strategies. Pharmacoeconomics. 2011;29(7):563-77.
5. NICE. Appraising treatments which may extend life, at the end of life. National Institute of Health and Clinical Excellence. 2011. http://www.nice.org. uk/aboutnice/howwework/devnicetech/endoflifetreatments.jsp. Accessed 15th November 2012.
6. Claxton K, Palmer S, Longworth L, Bojke L, Griffin S, McKenna C, et al. Uncertainty, evidence and irrecoverable costs: informing approval, pricing and research decisions for health. Centre for Health Economics Research Paper 69. York: University of York; 2011.
7. Stafinski T, McCabe C, Menon D. Funding the unfundable: mechanisms for managing uncertainty in decisions on the introduction of new and innovative technologies into health care systems. Pharmacoeconomics. 2010;28(2):113-42.
8. NICE. NICE Patient Access Schemes Liaison Unit. 2011. http://www.nice.org.uk/aboutnice/howwework/paslu/ patientaccessschemesliaisonunit.jsp. Accessed September 2012.
9. Claxton K, Ginnelly L, Sculpher M, Philips Z, Palmer S. A pilot study of the use of decision theory and value of information analysis as part of the NHS Health Technology Assessment Programme. Health Technol Assess. 2004;8(31):1-103.
10. Hall P, Edlin R, Kharroubi S, Gregory W, McCabe C. Expected net present value of information: from burden to investment. Med Decis Mak. 2012;32(3):E11-21.
11. Hall P, Hulme C, McCabe C, Oluboyede Y, Round J, Cameron D. Updated cost-effectiveness analysis of trastuzumab for early breast cancer: a UK perspective considering long-term toxicity and patterns of recurrence. Pharmacoeconomics. 2011;29(5):415-32.
12. Stinnett A, Mullahy J. Net health benefits: a new framework for the analysis of uncertainty in cost effectiveness analysis. Med Decis Mak. 1998;18(2):S68-90. (Pubitemid 28175944)
13. Claxton K, Paulden M, Gravelle H, Brouwer W, Culyer A. Discounting and decision making in the economic evaluation of health-care technologies. Health Econ. 2010;20:2-15.
14. Walker S, Sculpher M, Claxton K, Palmer S. Coverage with evidence development, only in research, risk sharing or patient access scheme? A framework for coverage decisions. Value Health. 2012;15(3):570-9.
15. McCabe C, Edlin R, Stafinski T, Menon D. Access with evidence development schemes: a framework for design and evaluation. Pharmacoeconomics. 2010;28(2):143-52.
16. Brouwer W, Niessen L, Postma M, Rutten F. Need for differential discounting of costs and health effects in cost effectiveness analyses. Br Med J. 2005;331:446-8. (Pubitemid 41176388)
17. Claxton K, Sculpher M, Culyer A, McCabe C, Briggs A, Akehurst R, et al. Discounting and cost-effectiveness in NICE: stepping back to sort out a confusion. Health Econ. 2006;15(1):1-4. (Pubitemid 43141521)
18. Jonsson P, Roberts J. Briefing paper for the methods review group working party on discounting. London: National Institute for Health and Clinical Excellence; 2011.
19. NICE Citizens Council. How should NICE assess future costs and benefits? http://www.nice.org.uk/media/06B/B8/Citizens-Council-report-on-Discounting.pdf (2011). Accessed 15th November 2012.
20. Claxton K, Briggs A, Buxton M, Culyer A, McCabe C, Walker S, et al. Value based pricing for NHS drugs: an opportunity not to be missed? Br Med J. 2008;336(7638):251-4. (Pubitemid 351251624)
21. O'Brien B, Briggs A. Analysis of uncertainty in health care cost-effectiveness studies: an introduction to statistical issues and methods. Stat Methods Med Res. 2002;11(6):455-68. (Pubitemid 36096865)
22. NICE. Guide to the methods of health technology. London: National Institute for Health and Clinical Excellence; 2008.
23. Huseraeu DF, Augustovski F, Briggs AH, Carswell C, Drummond M, et al. Consolidated Health Economic Evaluation Reporting Standards (CHEERS): exploration and elaboration. An ISPOR Task Force Report [draft]. http://www.ispor.org/taskforces/documents/ISPOR-Health-Econ-Eval-Pub-Guidelines- CHEERS-draft-for-review.pdf. Accessed 24th June 2013.
24. NICE Patient Access Scheme Liaison Unit. http://www.nice.org.uk/ aboutnice/howwework/paslu/patientaccessschemesliaisonunit.jsp. Accessed 24th June 2013.